BioSpace News Archive

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host a conference call and webcast at 4:30 p.m. ET on Monday, March 28, 2022, to discuss its financial and operating results for the fourth quarter and full year of 2021.

Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2021 as well as certain other business highlights.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with advanced solid tumors.

The healthcare sector is embracing the mobile imaging technology for its excellent contribution to patient care.

AnaptysBio, Inc. (Nasdaq: ANAB), today announced that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne, also known as the ACORN trial, did not demonstrate efficacy over placebo on primary or secondary endpoints.

Adaptive Research, an integrated clinical trial site organization with a unique purpose to democratize clinical trials by integrating community physicians into the clinical trial process, announced the addition of Christine Wong, MD as Director, External Affairs; and Claude Nguyen, MD as Director, Clinical Informatics to the Company’s operations teams.

DBV Technologies, a clinical-stage biopharmaceutical company, announced that Dr. Pharis Mohideen, Chief Medical Officer, will present at the Oppenheimer’s 32nd Annual Healthcare Conference on Thursday, March 17th at 10:00 a.m. ET.

DUBAI, United Arab Emirates, According to the latest market study of Future Market Insights, the global Multi-Parameter Patient Monitoring Market is expected to reach the valuation of US$ 6.1 billion by the end of 2028.

Spruce Biosciences, Inc. announced that Will Charlton, M.D., M.A.S., has been appointed Chief Medical Officer, and will succeed Rosh Dias, M.D., who has stepped down to pursue other opportunities.

Cano Health, Inc., a leading value-based primary care provider and population health company, announced financial results for the fourth quarter and full year ended December 31, 2021.